BANK VONTOBEL/CALL/NOVO NORDISK ADR B/145/0.1/21.03.25 | Market Closed - Bid/Ask 02:32:23 2024-07-17 am EDT | After market 03:36:35 pm | |||
| 1.43 EUR | -4.03% |
|
1.195 | -16.43% |
| Current month | -14.86% | ||
| 1 month | -9.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 1.43 | -4.03% |
| 24-07-16 | 1.49 | -5.70% |
| 24-07-15 | 1.58 | +9.72% |
| 24-07-12 | 1.44 | +0.70% |
| 24-07-11 | 1.43 | +1.42% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 02:32 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD3N4W |
| ISIN | DE000VD3N4W2 |
| Date issued | 2024-04-08 |
| Strike | 145 $ |
| Maturity | 2025-03-21 (247 Days) |
| Parity | 10 : 1 |
| Emission price | 1.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.83 € |
|---|---|
| Lowest since issue | 0.91 € |
| Spread | 0.01 € |
| Spread % | 0.83% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
